Beverly Hills, CANCT06884865Now EnrollingIRB Ready

Knee Osteoarthritis Clinical Trial in Beverly Hills, CA

Access cutting-edge knee osteoarthritis treatment through this phase 2 clinical trial at a research site in Beverly Hills. Study-provided care at no cost to qualified participants.

Sponsored by Pacira Pharmaceuticals, Inc

Quick Self-Assessment

See if you qualify for this Beverly Hills location

Preparing your pre-screening questions…

Expert Care in Beverly Hills

Access knee osteoarthritis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related knee osteoarthritis treatment provided free

Apply for This Beverly Hills Location

Check if you qualify for this knee osteoarthritis clinical trial in Beverly Hills, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Beverly Hills

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Beverly Hills site if eligible
  4. 4Begin participation

About This Knee Osteoarthritis Study in Beverly Hills

The goal of this clinical trial is to learn if a single knee injection of different doses (Dose A and Dose B) of an investigation product PCRX-201, following steroid pretreatment, is safe and tolerable in male of female patients 45 to 80 years old with osteoarthritis of the knee. It will also learn how the body reacts to the PCRX-201 injection and how effective the treatment is. Researchers will compare Dose A and Dose B of PCRX-201 versus placebo from Week 1 through Week 52 to assess adverse e

Sponsor: Pacira Pharmaceuticals, Inc

Who Can Participate

Inclusion Criteria

Subjects must be willing and able to comply with the study procedures and visit schedule and able to follow verbal and written instructions.
Subjects must be male or female and 45 to 80 years old, inclusive, at Screening.
Subjects must exhibit symptoms associated with osteoarthritis of the index knee for ≥12 months before Screening (subject self-reporting is acceptable).
Subjects must have index knee pain for \>15 days over the last month before Screening (subject self-reporting is acceptable).
Subjects must have received 2 or more failed 2 or more therapies: Restricted physical activity as per Osteoarthritis Research Society International (OARSI) core level recommendation, ie, "structured land-based exercise" (this may include physical therapy), and failure of an additional type of conservative therapy for OA of the index knee, eg, nonselective NSAIDs or COX-2 inhibitors, in the past 12 months.
Subjects must have a body mass index (BMI) ≤40 kg/m2 at Screening.
Subjects must have an index knee examination indicating the index knee and the intended injection site area are free of any signs of local or joint infection at Baseline.
Subjects must have an index knee Average Daily Knee Pain (NRS) between ≥5.0 and ≤9.0 at Screening and Baseline.
Sexually active subjects of child-bearing potential (SOCBP) and their partners must agree to use effective birth control while in the study
Subjects must have active synovitis in the index knee as determined by ultrasound Doppler (Part A only) For Part B, participants must have active synovitis in the index knee as determined by contrast-enhanced MRI.
Subjects must exhibit American College of Rheumatology Criteria (clinical and radiological) for osteoarthritis as follows:
At least 1 of the following: i. Age \>50 years ii. Morning stiffness \<30 minutes iii. Crepitus on knee motion c. Osteophytes
Subjects must have K-L Grade 2, 3, or 4 (Part A) or K-L Grade 2 or 3 (Part B) in the index knee based on X-rays performed during Screening and confirmed by trained radiographers at a central facility before enrollment
Subjects need to show the presence of moderate or severe synovitis based on 11-point synovitis score using contrast-enhanced MRI (Part A). For Part B, participants need to show the presence of synovitis ≥5 on the Guermazi synovitis scoring scale using contrast-enhanced MRI to be enrolled.

Exclusion Criteria

Subjects have any current or prior diagnosis of autoimmune connective tissue disorders, secondary OA conditions, benign synovial tumors, gout/pseudogout, reactive arthritis, RA, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease.
Subjects have any active systemic or local infection, including infection of the index knee
Subjects are unable to undergo MRI with contrast MRI
Subjects with X-ray or MRI exclusionary events
Subjects have an unstable index knee joint (eg, torn anterior cruciate ligament) within 12 months of Screening
Subjects have used any approved or investigational IA drug/biologic in index knee within 6 months of Screening (eg, hyaluronic acid, platelet rich plasma, stem cells, prolotherapy, and amniotic fluid injection)
Subjects are receiving or have received any gene therapy treatment (eg, IL-1Ra) in the past 3 years
Subjects have used IA steroids ≤3 months before screening
For Part B, subjects with any surgery related tot he index knee. Other protocol-defined criteria apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Beverly Hills?

Yes, this clinical trial (NCT06884865) has an active research site in Beverly Hills, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Knee Osteoarthritis Treatment Options in Beverly Hills, CA

If you're searching for knee osteoarthritis treatment options in Beverly Hills, CA, this clinical trial (NCT06884865) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Beverly Hills research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced knee osteoarthritis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all knee osteoarthritis clinical trials near you to find additional studies recruiting in your area.

More Osteoarthritis Trials in Beverly Hills, CA

See all osteoarthritis clinical trials recruiting in Beverly Hills — not just this study.

Browse Osteoarthritis Trials in Beverly Hills →

Browse More Trials by Condition

Osteoarthritis TrialsAll Conditions →

Ready to Join in Beverly Hills?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Beverly Hills, CA